A groundbreaking ceremony for the Xigduo XR product, operated by the Taizhou factory of AstraZeneca, took place on June 18 in Taizhou Medical City, Taizhou, Jiangsu province. It is expected to help turn the Taizhou factory into the global production and supply base of AstraZeneca's diabetes drugs.
With an investment of 190 million yuan ($26.52 million), the project will build new production lines and continue to introduce diabetes drug production supply chain.
A groundbreaking ceremony for the Xigduo XR product takes place on June 18. [Photo/WeChat account: weigg6666]
Xigduo XR is an original drug developed by AstraZeneca and was approved for market in China in 2023. In addition to its hypoglycemic effect, the drug also reduces risk of heart and kidney disease, making the treatment of diabetes easier.
AstraZeneca is a global biopharmaceutical company driven by innovation, focusing on core disease areas of oncology, cardiovascular and metabolic diseases, and respiratory and immunotherapy.
AstraZeneca's Taizhou factory was established in China Medical City in 2012 and put into operation in 2014. It is AstraZeneca's largest single investment project in Jiangsu to date.